Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Matinas BioPharma Holdings, Inc. (MTNB)
Price—Loading quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.1M | $3.2M | $33,000 | $158,333 | $89,812 | $119,750 | $149,687 | $0 | $194,494 | $0 | — |
| Research & development | $85,000 | $11.4M | $14.5M | $16.7M | $14.6M | $14.4M | $11.2M | $6.8M | $9.0M | $3.9M | $5.3M | $5.2M | $1.8M |
| Operating expenses | $7.0M | $20.2M | $24.9M | $27.8M | $24.8M | $24.4M | $19.0M | $14.8M | $16.7M | $8.3M | $10.1M | $10.5M | $3.7M |
| Operating income | −$7.0M | −$24.6M | −$23.8M | −$24.6M | −$24.7M | −$24.2M | −$18.9M | −$14.6M | −$16.5M | −$8.3M | −$9.9M | −$10.5M | −$3.7M |
| Operating margin | — | — | −2,168.43% | −771.33% | −74,954.55% | −15,288.38% | −21,067.38% | −12,230.94% | −11,024.61% | — | −5,096.04% | — | — |
| EBITDA | −$6.9M | −$24.2M | −$23.4M | −$24.3M | −$24.5M | −$24.0M | −$18.7M | −$14.4M | −$16.4M | −$8.2M | −$9.9M | −$10.4M | −$3.7M |
| EBITDA margin | — | — | −2,133.30% | −760.76% | −74,215.15% | −15,142.45% | −20,838.05% | −12,048.63% | −10,957.40% | — | −5,073.68% | — | — |
| Net income | −$10.3M | −$24.3M | −$22.9M | −$21.0M | −$23.3M | −$22.4M | −$17.4M | −$14.1M | −$15.5M | −$7.6M | −$9.1M | −$10.2M | −$3.7M |
| Net profit margin | — | — | −2,093.25% | −658.63% | −70,554.55% | −14,176.98% | −19,343.35% | −11,760.39% | −10,345.91% | — | −4,697.01% | — | — |
| Basic EPSper basic share | -$2.00 | -$4.98 | -$5.28 | -$5.00 | -$5.50 | -$6.00 | -$6.50 | -$7.50 | -$18.00 | -$10.50 | -$9.00 | -$16.00 | -$10.00 |
| Diluted EPSper diluted share | -$2.00 | -$4.98 | -$5.28 | -$5.00 | -$5.50 | -$6.00 | -$6.50 | -$7.50 | -$18.00 | -$10.50 | -$9.00 | -$16.00 | -$10.00 |
Owners
Reported shareholders
≈3.29%of listed shares
STERN ADAM K210.69K shares · Feb 13, 2025
View holders
| Holder | % owned |
|---|---|
STERN ADAM K | ≈3.29%210.69K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.11%71.04K shares |
BlackRock, Inc. | 0.78%50.26K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.77%49.14K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.63%40.11K shares |
Holos Integrated Wealth LLC | 0.51%32.48K shares |
VANGUARD FIDUCIARY TRUST CO | 0.27%17.32K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.25%16.09K shares |
CITADEL ADVISORS LLC | 0.24%15.47K shares |
STATE STREET CORP | 0.24%15.32K shares |
Sargent Investment Group, LLC | 0.20%12.72K shares |
Tower Research Capital LLC (TRC) | 0.04%2.85K shares |
EIDE ROBERT J | ≈0.02%1.5K shares |
Vanguard Global Advisers, LLC | 0.02%1.34K shares |
MORGAN STANLEY | <0.01%344 shares |
Costello Asset Management, INC | <0.01%200 shares |
WELLS FARGO & COMPANY/MN | <0.01%102 shares |
JONES FINANCIAL COMPANIES LLLP | <0.01%60 shares |
EverSource Wealth Advisors, LLC | <0.01%60 shares |
OSAIC HOLDINGS, INC. | <0.01%52 shares |
Percentages use 6.41M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2025Form 4/A | Sanitam Partners LLCTenPercentOwner | BuyWarrants · derivative | 2.40M | — | — | 4.80M |
| Apr 8, 2025Form 4/A | Sanitam Partners LLCTenPercentOwner | BuySeries C Convertible Preferred Stock · derivative | 703 | $1.0K | $703.0K | 1.4K |
| Apr 8, 2025Form 4/A | EIDE ROBERT JTenPercentOwner | BuyWarrants · derivative · indirect | 1.68M | — | — | 3.36M |
| Apr 8, 2025Form 4/A | EIDE ROBERT JTenPercentOwner | BuySeries C Convertible Preferred Stock · derivative · indirect | 492 | $1.0K | $492.0K | 984 |
| Apr 8, 2025Form 4/A | Pembroke & Partners LLCTenPercentOwner | BuyWarrants · derivative | 1.68M | — | — | 3.36M |